ASGCT’s Q1 2026 landscape report, presented by CEO David Barrett with support from Citeline, points to a “rebounding sector” for gene and RNA therapies. The report highlights 42 gene therapies approved worldwide and 38 RNA therapies, alongside 76 non-genetically modified cell therapies, and it notes a 30% increase in startup funding year-over-year for the quarter. Regulatory momentum appears to be returning as well: of eight gene therapies approved in the past 12 months, half were in the U.S. and three in China. The society also reported growth in clinical trials, including 350 Phase I, 319 Phase II, and 41 Phase III gene therapy trials, with a growing share aimed at non-oncology indications. In the RNA space, the report says RNAi therapies are increasing, while mRNA growth is comparatively slower. Across gene-modified cell therapies, CAR T remains the dominant ex vivo gene therapy platform, with NK and T-cell receptor programs gaining traction. The report’s near-term emphasis is on completed trials and upcoming FDA decisions, setting expectations for additional approvals as the clinical pipeline matures.